Other
Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross
Vertex Pharmaceuticals Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross remained flat by 0.0% to -$1.85M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 562.5%, from $400.00K to -$1.85M. Over 2 years (FY 2023 to FY 2025), Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross shows a downward trend with a 41.4% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Changes here provide insight into how the company's tax planning strategies affect the recoverability of deferred tax assets.
Detailed definition
Reflects the gross change in deferred tax assets that are associated with unrecognized tax benefits. This metric highlig...
Peer comparison
Standard tax footnote disclosure for companies with complex deferred tax asset structures.
Metric ID:
other_unrecognized_tax_benefits_increase_decrease_in_def_4b520cHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $3.70M | $1.60M | -$7.40M |
| YoY Change | — | -56.8% | -562.5% |
Range-$7.40M – $3.70M
CAGR+41.4%
Avg YoY Growth-309.6%
Median YoY Growth-309.6%
Current Streak2+ years decline
Unrecognized tax benefits, increase (decrease) in deferred tax assets, gross at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's unrecognized tax benefits, increase (decrease) in deferred tax assets, gross?
- Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits, increase (decrease) in deferred tax assets, gross of -$1.85M in Q4 2025.
- How has Vertex Pharmaceuticals's unrecognized tax benefits, increase (decrease) in deferred tax assets, gross changed year-over-year?
- Vertex Pharmaceuticals's unrecognized tax benefits, increase (decrease) in deferred tax assets, gross decreased by 562.5% year-over-year, from $400.00K to -$1.85M.
- What is the long-term trend for Vertex Pharmaceuticals's unrecognized tax benefits, increase (decrease) in deferred tax assets, gross?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's unrecognized tax benefits, increase (decrease) in deferred tax assets, gross has grown at a 41.4% compound annual growth rate (CAGR), from $3.70M to -$7.40M.
- What does unrecognized tax benefits, increase (decrease) in deferred tax assets, gross mean?
- The change in the value of future tax assets related to uncertain tax positions.